Home/Clinical Trials
RecruitingPhase 2CT-2026-121
Gene therapy CLV-508 in ambulatory boys with Duchenne
Duchenne muscular dystrophy · Rare Disease
Ages 4 to 17 years230 participantsSydney, Australia, Houston, TX
RecruitingPhase 3CT-2026-101
Emzaratinib after surgery in early-stage lung cancer
Non-small cell lung cancer · Oncology
Ages 18 years and older740 participantsChicago, IL, London, UK +2 more
RecruitingPhase 3CT-2023-112
Subcutaneous trelanemab in early Alzheimer's disease
Alzheimer's disease · Neuroscience
Ages 50 to 85 years950 participantsChicago, IL, Berlin, Germany
RecruitingPhase 2CT-2025-114
CLV-318 in treatment-resistant depression
Depression · Neuroscience
Ages 18 to 80 years230 participantsHouston, TX, Sydney, Australia +1 more
RecruitingPhase 1CT-2025-122
CLV-515 in adults with Fabry disease
Fabry disease · Rare Disease
Ages 18 years and older80 participantsSeoul, South Korea, San Diego, CA +2 more
RecruitingPhase 3CT-2024-111
Solekizumab in children with plaque psoriasis
Plaque psoriasis · Immunology
Ages 4 to 17 years1,230 participantsBerlin, Germany, Boston, MA
RecruitingPhase 3CT-2023-116
Once-weekly lorvatide in adults with obesity
Obesity · Cardiometabolic
Ages 18 years and older730 participantsBoston, MA, San Diego, CA +3 more
RecruitingPhase 3CT-2026-105
Tazulimab-cvra in newly diagnosed multiple myeloma
Multiple myeloma · Oncology
Ages 18 years and older1,120 participantsToronto, Canada, Raleigh, NC +1 more
RecruitingPhase 2CT-2023-108
CLV-226 in adolescents and adults with atopic dermatitis
Atopic dermatitis · Immunology
Ages 12 years and older370 participantsBerlin, Germany, London, UK +1 more
RecruitingPhase 2CT-2025-102
Bispecific CLV-140 in extensive-stage small cell lung cancer
Small cell lung cancer · Oncology
Ages 18 years and older290 participantsLondon, UK, Sydney, Australia
RecruitingPhase 1CT-2026-109
CAR-T cell therapy CLV-233 in refractory lupus
Systemic lupus erythematosus · Immunology
Ages 18 to 80 years50 participantsTokyo, Japan, Berlin, Germany +2 more
RecruitingPhase 2CT-2025-118
CLV-419 in heart failure with preserved ejection fraction
Heart failure · Cardiometabolic
Ages 18 to 75 years270 participantsToronto, Canada, Tokyo, Japan +2 more
Active, not recruitingPhase 3CT-2024-115
Long-term extension of trelanemab
Alzheimer's disease · Neuroscience
Ages 50 to 85 years1,600 participantsBerlin, Germany, Seoul, South Korea
Active, not recruitingPhase 3CT-2026-117
Semavotide in obesity with type 2 diabetes
Obesity · Cardiometabolic
Ages 18 to 80 years1,130 participantsMadrid, Spain, Raleigh, NC +1 more
Active, not recruitingPhase 3CT-2024-123
Elvoparvec 15-year follow-up registry
Spinal muscular atrophy · Rare Disease
Ages 18 to 75 years2,140 participantsSydney, Australia, Boston, MA +2 more
Active, not recruitingPhase 3CT-2024-107
Corvatinib in moderate-to-severe Crohn's disease
Crohn's disease · Immunology
Ages 18 to 75 years1,910 participantsMadrid, Spain, Berlin, Germany +2 more
Active, not recruitingPhase 2CT-2025-106
Orevantinib in VRX-1 positive colorectal cancer
Colorectal cancer · Oncology
Ages 18 years and older170 participantsToronto, Canada, Berlin, Germany +3 more
Active, not recruitingPhase 3CT-2023-120
Calvasiran cardiovascular outcomes study
Hyperlipidemia · Cardiometabolic
Ages 18 years and older2,940 participantsSan Diego, CA, Madrid, Spain
Active, not recruitingPhase 1CT-2024-103
First-in-human study of CLV-147 in platinum-resistant ovarian cancer
Ovarian cancer · Oncology
Ages 18 years and older70 participantsSeoul, South Korea, Sydney, Australia +1 more
Active, not recruitingPhase 3CT-2026-113
CLV-310 in early Parkinson's disease
Parkinson's disease · Neuroscience
Ages 50 to 85 years2,280 participantsToronto, Canada, Seoul, South Korea +3 more
Not yet recruitingPhase 1CT-2026-125
CLV-140 in neuroendocrine tumors
Neuroendocrine tumors · Oncology
Ages 18 years and older30 participantsBerlin, Germany, Seoul, South Korea
Not yet recruitingPhase 2CT-2025-126
CLV-226 in prurigo nodularis
Prurigo nodularis · Immunology
Ages 18 to 75 years350 participantsBerlin, Germany, Chicago, IL +1 more
Not yet recruitingPhase 2CT-2024-127
CLV-318 relapse-prevention study
Depression · Neuroscience
Ages 18 to 75 years160 participantsSydney, Australia, Chicago, IL
Not yet recruitingPhase 2CT-2026-129
CLV-508 in non-ambulatory patients
Duchenne muscular dystrophy · Rare Disease
Ages 18 years and older210 participantsLondon, UK, San Diego, CA +1 more
CompletedPhase 3CT-2023-104
Berolumab-cvra versus chemotherapy in HER-low breast cancer
Breast cancer · Oncology
Ages 18 years and older2,030 participantsHouston, TX, London, UK +1 more
CompletedPhase 3CT-2025-110
Teravolumab in hidradenitis suppurativa
Hidradenitis suppurativa · Immunology
Ages 18 to 75 years3,000 participantsSeoul, South Korea, Tokyo, Japan +2 more
CompletedPhase 1CT-2024-119
CLV-427 in adults with elevated Lp(a)
Cardiovascular disease · Cardiometabolic
Ages 18 to 80 years50 participantsChicago, IL, Raleigh, NC
CompletedPhase 3CT-2025-130
Solekizumab every-12-weeks dosing study
Plaque psoriasis · Immunology
Ages 18 to 80 years2,680 participantsMadrid, Spain, London, UK +2 more
CompletedPhase 3CT-2023-124
Emzaratinib plus chemotherapy in metastatic lung cancer
Non-small cell lung cancer · Oncology
Ages 18 years and older1,120 participantsToronto, Canada, Raleigh, NC +2 more
CompletedPhase 1CT-2023-128
CLV-419 biomarker study
Heart failure · Cardiometabolic
Ages 18 years and older90 participantsSeoul, South Korea, Toronto, Canada +3 more
Study listings are fictional. Talk with your doctor before joining any clinical trial.